Statin News and Research RSS Feed - Statin News and Research

Statins are drugs used to lower cholesterol. Your body needs some cholesterol to work properly. But if you have too much in your blood, it can stick to the walls of your arteries, narrowing or even blocking them.
Limited anticancer role for preoperative statins in localised RCC setting

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests. [More]
Discontinuation of statin therapy may benefit patients with terminal illness

Discontinuation of statin therapy may benefit patients with terminal illness

Discontinuing statin use in patients with late-stage cancer and other terminal illnesses may help improve patients' quality of life without causing other adverse health effects, according to a new study by led by researchers at the University of Colorado Anschutz Medical Campus and Duke University and funded by the National Institute of Nursing Research (NINR). [More]
Simultaneous use of hormones and statins can protect women from heart disease after menopause

Simultaneous use of hormones and statins can protect women from heart disease after menopause

Hormones may not protect women from heart disease or stroke after menopause, but when combined with cholesterol-lowering statin drugs, they may help protect women from these killers, shows a population study from Sweden to be published in the April issue of Menopause, the journal of The North American Menopause Society. [More]
Majority of doctors welcome additional training in diet, nutrition to prevent CVD

Majority of doctors welcome additional training in diet, nutrition to prevent CVD

Most physicians are aware of the importance of lifestyle factors in preventing cardiovascular disease (CVD) -- and believe diet is as important as statin therapy and exercise, according to a new survey from NYU Langone Medical Center. [More]
New statin guidelines may be too generic, shows study

New statin guidelines may be too generic, shows study

The newest guidelines for the use of cholesterol-lowering statins in people at risk of heart disease may be too generic, excluding middle-aged adults who could benefit from the drugs, and over-prescribing in older adults, according to a new study from the Duke Clinical Research Institute. [More]
Type 2 diabetes less common in patients with familial hypercholesterolemia

Type 2 diabetes less common in patients with familial hypercholesterolemia

The prevalence of type 2 diabetes among 25,000 patients with familial hypercholesterolemia (a genetic disorder characterized by high low-density lipoprotein [LDL] cholesterol levels) was significantly lower than among unaffected relatives, with the prevalence varying by the type of gene mutation, according to a study in the March 10 issue of JAMA. [More]
Screening for and treating depression could help reduce risk of heart disease

Screening for and treating depression could help reduce risk of heart disease

A new study by researchers at the Intermountain Medical Center Heart Institute has found that screening for and treating depression could help to reduce the risk of heart disease in patients with moderate to severe depression. [More]
New study shows who benefits most from statin therapy

New study shows who benefits most from statin therapy

Research has demonstrated that the risk for developing coronary heart disease depends on a host of risk factors that are related both to lifestyle and genetics. In a new study from Brigham and Women's Hospital, Washington University School of Medicine in St. Louis, and Massachusetts General Hospital, researchers tested whether a composite of genetic variants could identify the risk of cardiovascular death and heart attacks as well as identify individuals who derived greater clinical benefit from statin therapy. [More]
Ninety percent of patients at risk of CHD fail to receive statins

Ninety percent of patients at risk of CHD fail to receive statins

The study, published in Current Medical Research and Opinion, provides the first ever real-world view of the treatment landscape for patients at risk of CHD[1], with a sample of two million patients. But the results paint a bleak picture of prescribing patterns with the majority not being given the potentially life saving drug. [More]
Single-step fermentative method may facilitate industrial-scale statin drug production

Single-step fermentative method may facilitate industrial-scale statin drug production

University of Manchester researchers, together with industrial partner DSM, have developed a single-step fermentative method for the production of leading cholesterol-lowering drug, pravastatin, which will facilitate industrial-scale statin drug production. [More]
Beneficial effects of statin treatment exaggerated, say researchers

Beneficial effects of statin treatment exaggerated, say researchers

Hailed as miracle drugs when they hit the market two decades ago, statins, the cholesterol-lowering drugs prescribed to prevent heart attacks, are not as effective nor as safe as we have been led to believe, say Dr. David M. Diamond, a professor of psychology, molecular pharmacology and physiology at the University of South Florida, and Dr. Uffe Ravnskov, an independent health researcher and an expert in cholesterol and cardiovascular disease. [More]
New study finds that statins may not reduce risk for Parkinson's disease

New study finds that statins may not reduce risk for Parkinson's disease

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmental Health Sciences. The findings cast doubts on reports suggesting that the cholesterol-lowering medications may protect against this neurodegenerative brain disorder. [More]
Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens. [More]
Study: Most risk calculators used by clinicians overestimate risk of heart attack

Study: Most risk calculators used by clinicians overestimate risk of heart attack

Most "risk calculators" used by clinicians to gauge a patient's chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions. [More]
Widely used clinical calculators overrate heart attack risk

Widely used clinical calculators overrate heart attack risk

Most "risk calculators" used by clinicians to gauge a patient's chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions. [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Two new ODYSSEY trials meet primary efficacy endpoints

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Study explores association between statin use and cataracts

Study explores association between statin use and cataracts

Few classes of drugs have had such a transformative effect on the prevention of cardiovascular disease (CVD) as have statins, prescribed to reduce total cholesterol and low-density lipoprotein cholesterol. [More]
Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

A quality improvement initiative improved the outcomes of patients undergoing cardiac surgery at select medical centers in northern New England, according to a study in the December issue of Critical Care Nurse (CCN). [More]
Advertisement
Advertisement